The Competitive Intelligence Report Thrombopoiesis Stimulating Agents (TPO; IL-11) as of January 2011 provides information on thrombopoiesis stimulating agents targeting the thrombopoietin, interleukin-11 or other receptors on the market and in development.
Director of Research and Principal Investigator for the grant, stated, "We are delighted to receive continued support for our second generation interleukin-11 (IL-11) program from the National Cancer Institute.
In a study published in the July 1 issue of the Journal of Clinical Investigation, the researchers report that mice given interleukin-11 (IL-11) after receiving an allogeneic, or non-self, bone marrow transplant were protected from the effects of graft-versus-host disease, an often debilitating condition that can follow marrow transplants.
The grant, entitled "Cytokine Conjugates for Treating Thrombocytopenia", supports research to develop long-acting, second generation forms of interleukin-11 (IL-11) for the treatment of chemotherapy-induced thrombocytopenia.
Preliminary research presented today at the American Association for the Study of Liver Diseases annual meeting suggests that these patients can begin or continue treatment at full dosage and without interruption when also treated with the platelet growth factor Interleukin-11 (Oprelvekin, marketed under the brand name Neumega(R)).